FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2296842992> ?p ?o ?g. }

• W2296842992 endingPage "4132" @default.
• W2296842992 startingPage "4132" @default.
• W2296842992 abstract "4132 Background: The possible replacement of continuous infusion 5FU by the oral pro-drug capecitabine is controversial. The aim of this work was to study genetic polymorphisms and their role in tailoring fluroropyrimidine/oxaliplatin treatment in metastatic colorectal cancer (mCRC). Methods: A total of 110 patients participating in the clinical phase III trial done by the Spanish TTD group comparing the efficacy and safety of capecitabine plus oxaliplatin (XELOX) versus Spanish-based continuous-infusion high-dose 5FU plus oxaliplatin (FUOX) regimens as first-line therapy for mCRC, were selected prospectively for TS (5’VNTR, 5’SNP and 3’UTR), XRCC1–399, XPD-751, ERCC1–118 and XRCC3–241 genotyping. Genotypes were analyzed as codominant, dominant and recessive models. Contingency tables, Chi-square and Fisher’s exact test were used to evaluate the association of polymorphisms with categorical variables. The association of genetic variants and clinical parameters with progression free survival (PFS) was estimated by calculating HR and their 95% CI from univariate and multivariate Cox proportional hazards regression models. The differences were considered statistically significant when two- sided p-values were less than 0.05. Results: In the FUOX group, TS-3’UTR +6bp/+6bp and ERCC1–118 C/T or C/C genotypes correlated with a shorter PFS (HR = 2.62, 95% CI (1.3 - 5.3) p = 0.007 and, HR =1.96, 95% CI (0.99 - 3.92) p = 0.050). When analyzed jointly, the higher the number of favorable genotypes (FG) the longer the PFS (6.8 m for 0 FG (group 3), 9.6 m for 1 FG (group 2) and 25.8 m for 2 FG (group 1); p = 0.005, group 2 HR = 2.57, 95% CI 0.94–7; group 3 HR = 5.63, 95% CI 1.92–16.53). Disease-control rate was higher in group 1 (100% vs. 87% group 2 and 38.5% group 3; p = 0.001). In the multivariate analysis, ERCC1–118 C/T or C/C (p = 0.0037) and TS-3’UTR +6bp/+6bp (p = 0.006) were strong independent prognostic factors. No differences were found in the XELOX group in which median PFS for the equivalent group 3 was 10.2 months. Conclusions: According to this, mCRC patients harboring TS- 3’UTR +6bp/+6bp and ERCC1–118 C/T or C/C genotypes may better receive capecitabine instead of 5FU in an oxaliplatin-based first line treatment. No significant financial relationships to disclose." @default.
• W2296842992 created "2016-06-24" @default.
• W2296842992 creator A5003577218 @default.
• W2296842992 creator A5005273655 @default.
• W2296842992 creator A5008522699 @default.
• W2296842992 creator A5013896384 @default.
• W2296842992 creator A5032860719 @default.
• W2296842992 creator A5037729211 @default.
• W2296842992 creator A5057435612 @default.
• W2296842992 creator A5060170484 @default.
• W2296842992 creator A5068189051 @default.
• W2296842992 creator A5073742272 @default.
• W2296842992 creator A5079210916 @default.
• W2296842992 date "2008-05-20" @default.
• W2296842992 modified "2023-09-23" @default.
• W2296842992 title "Pharmacogenetic approach for capecitabine or 5-fluorouracil (5FU) selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer" @default.
• W2296842992 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.4132" @default.
• W2296842992 hasPublicationYear "2008" @default.
• W2296842992 type Work @default.
• W2296842992 sameAs 2296842992 @default.
• W2296842992 citedByCount "0" @default.
• W2296842992 crossrefType "journal-article" @default.
• W2296842992 hasAuthorship W2296842992A5003577218 @default.
• W2296842992 hasAuthorship W2296842992A5005273655 @default.
• W2296842992 hasAuthorship W2296842992A5008522699 @default.
• W2296842992 hasAuthorship W2296842992A5013896384 @default.
• W2296842992 hasAuthorship W2296842992A5032860719 @default.
• W2296842992 hasAuthorship W2296842992A5037729211 @default.
• W2296842992 hasAuthorship W2296842992A5057435612 @default.
• W2296842992 hasAuthorship W2296842992A5060170484 @default.
• W2296842992 hasAuthorship W2296842992A5068189051 @default.
• W2296842992 hasAuthorship W2296842992A5073742272 @default.
• W2296842992 hasAuthorship W2296842992A5079210916 @default.
• W2296842992 hasConcept C121608353 @default.
• W2296842992 hasConcept C126322002 @default.
• W2296842992 hasConcept C143998085 @default.
• W2296842992 hasConcept C2776694085 @default.
• W2296842992 hasConcept C2777909004 @default.
• W2296842992 hasConcept C2779268555 @default.
• W2296842992 hasConcept C2780456651 @default.
• W2296842992 hasConcept C2780962732 @default.
• W2296842992 hasConcept C50382708 @default.
• W2296842992 hasConcept C526805850 @default.
• W2296842992 hasConcept C71924100 @default.
• W2296842992 hasConceptScore W2296842992C121608353 @default.
• W2296842992 hasConceptScore W2296842992C126322002 @default.
• W2296842992 hasConceptScore W2296842992C143998085 @default.
• W2296842992 hasConceptScore W2296842992C2776694085 @default.
• W2296842992 hasConceptScore W2296842992C2777909004 @default.
• W2296842992 hasConceptScore W2296842992C2779268555 @default.
• W2296842992 hasConceptScore W2296842992C2780456651 @default.
• W2296842992 hasConceptScore W2296842992C2780962732 @default.
• W2296842992 hasConceptScore W2296842992C50382708 @default.
• W2296842992 hasConceptScore W2296842992C526805850 @default.
• W2296842992 hasConceptScore W2296842992C71924100 @default.
• W2296842992 hasIssue "15_suppl" @default.
• W2296842992 hasLocation W22968429921 @default.
• W2296842992 hasOpenAccess W2296842992 @default.
• W2296842992 hasPrimaryLocation W22968429921 @default.
• W2296842992 hasRelatedWork W1974190027 @default.
• W2296842992 hasRelatedWork W1987484549 @default.
• W2296842992 hasRelatedWork W1997133872 @default.
• W2296842992 hasRelatedWork W2000578400 @default.
• W2296842992 hasRelatedWork W2007576124 @default.
• W2296842992 hasRelatedWork W2029040122 @default.
• W2296842992 hasRelatedWork W2075077394 @default.
• W2296842992 hasRelatedWork W2318835985 @default.
• W2296842992 hasRelatedWork W2556312195 @default.
• W2296842992 hasRelatedWork W349909140 @default.
• W2296842992 hasVolume "26" @default.
• W2296842992 isParatext "false" @default.
• W2296842992 isRetracted "false" @default.
• W2296842992 magId "2296842992" @default.
• W2296842992 workType "article" @default.